Drug Trial Radar · NCT05181462
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
117
Actual
Start
Jan 11, 2022
Primary completion
Apr 9, 2026
Study completion May 8, 2026
Sponsor
- Lead sponsor
- Cantargia ABIndustry
- Sponsor type
- Industry
- Collaborators
- Spanish Breast Cancer Research Group
- First posted
- Jan 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) worldwide. The term triple negative means that tumor growth is not stimulated by the hormones estrogen and progesterone, nor by the HER2 protein, so unlike other types of BC, TNBC, which is an aggressive form of BC, does not have specific effective therapies available being the least common form of BC and the most difficult to treat. Advanced or metastatic TNBC is treated with combinations of platinum-based chemotherapy with taxanes or gemcitabine with a 5-year survival rate of 12%. Recent studies have shown that TNBC expresses Interleukin 1 Receptor Accessory Protein (IL1RAP) at higher levels than other forms of BC. Nadunolimab is a fully humanized monoclonal antibody that blocks the signals that occur within the cell produced by IL1RAP protein, thereby impairing the cancer cells' ability to secrete tumor stimulating substances, in turn reducing the tumor, inflammation and tumor progression. On the other hand, it is an antibody designed to activate the immune system to fight cancer cells. This clinical trial is divided into two phases, phase Ib in which it is expected to include up to 15 patients and phase II in which it is expected to include 102 patients. The main purpose of phase Ib is to ensure that the combination of nadunolimab plus chemotherapy (gemcitabine plus carboplatin) is safe and determine the highest dose of nadunolimab that can be given safely without causing serious side effects. If the pre-specified objectives in this part are achieved, the trial will be expanded to a randomized phase II, to evaluate the efficacy of the combination of nadunolimab plus gemcitabine plus carboplatin, compared to a control group that will receive gemcitabine plus carboplatin only.
Conditions
- Triple Negative Breast Cancer
Interventions
CarboplatinDrug
Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8/15, in cycles of 3-4 weeks
GemcitabineDrug
Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks
NadunolimabDrug
Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8/15, in cycles of 3-4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence rate of Dose Limiting Toxicity (DLT) within the first cycle of nadunolimab in combination with gemcitabine plus carboplatinTime frame: At the end of Cycle 1 (each cycle is 21 days)
- Objective Response Rate (ORR)Time frame: Through study completion, an average of 58 months
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitario Virgen de las Nieves
Granada, Andalusia, Spain
Hospital Universitario Clinico San Cecilio
Granada, Andalusia, Spain
Complejo Hospitalario de Jaén
Jaén, Andalusia, Spain
Hospital Universitario Virgen De La Victoria
Málaga, Andalusia, Spain
Hospital Universitario Virgen Macarena
Seville, Andalusia, Spain
Hospital Universitario Virgen Del Rocío
Seville, Andalusia, Spain
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Aragon, Spain
Onkologikoa
Donostia / San Sebastian, Basque Country, Spain
Complejo Hospitalario Universitario de Albacete
Albacete, Castille-La Mancha, Spain
Hospital Universitario de Toledo
Toledo, Castille-La Mancha, Spain
Hospital del Mar
Barcelona, Catalonia, Spain
Hospital Clinic de Barcelona
Barcelona, Catalonia, Spain
ICO Institut Catalá d'Oncologia de L´Hospitalet
Hospitalet de Llobregat, Barcelona, Catalonia, Spain
Hospital Universitario Arnau de Vilanova Lleida
Lleida, Catalonia, Spain
Complejo Hospitalario Universitario A Coruña
A Coruña, Galicia, Spain
Hospital Universitario Lucus Augusti
Lugo, Galicia, Spain
Hospital Materno Infantil de Gran Canaria
Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Universitario Gregorio Marañón
Madrid, Madrid, Spain
Hospital Clínico San Carlos
Madrid, Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain
Clínica Universidad de Navarra
Pamplona, Navarre, Spain
Hospital Universitario San Juan de Alicante
Alicante, Valencia, Spain
Fundación Instituto Valenciano de Oncología
Valencia, Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.